Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer Original Research Article

Background Adjuvant chemotherapy can improve 5-year survival in Dukesʹ C colorectal carcinoma. Improved selection of patients who will respond to adjuvant treatments is required. We investigated whether site of tumour origin, sex, and presence of microsatellite instability (MSI) phenotype were associated with a survival benefit from adjuvant chemotherapy. Methods We analysed data for 656 consecutive patients with Dukesʹ C colorectal carcinoma, with median follow-up of 54 months (range 7–104) and mean age 66·7 years (SD 12·9). We screened tumour samples by PCR for deletions in the BAT-26 mononucleotide repeat to establish MSI status. Details of chemotherapy and survival were obtained by review of hospital and health-department records. Adjuvant chemotherapy (fluorouracil and levamisole) was given with curative intent to 272 (42%) patients. Findings Striking survival benefits were seen for patients who had right-sided tumours and who received adjuvant chemotherapy compared with those who did not (48 vs 27% alive at end of study [95% Cl 0·25–0·56], p<·0001), for women (53 vs 33% [0·25–0·56], p<0·0001), and for patients with MSI tumours (90 vs 35% [0·01–0·53], p=0·0007). MSI-positive tumours were slightly more frequent in women than in men (10 vs 7%). Right-sided tumours were more frequently MSI positive than left-sided tumours (20 vs 1%). Men with right-sided tumours benefited from chemotherapy (37 vs 12% [0·24–0·69], p=0·0007) but men with left-sided tumours did not. Interpretation The survival benefits seen in patients treated with adjuvant chemotherapy suggest that data from previous trials of adjuvant chemotherapy should be reassessed and the predictive value of MSI status confirmed. Validation of our results will allow better selection of patients for chemotherapy